The clinical development of omnic (tamsulosin) oral controlled absorption system (OCAS®)

被引：5

作者：

Speakman, M ^{[1
]}

机构：

[1] Taunton & Somerset Hosp, Taunton TA1 5DA, Somerset, England

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2005年 / 4卷 / 07期

关键词：

tamsulosin; oral controlled absorption system; modified release formulation; placebo; review; randomised controlled trial; efficacy; safety;

D O I：

10.1016/j.eursup.2005.07.004

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：5 / 9

页数：5

共 13 条

[1] Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system [J].

Barendrecht, MM ;

Koopmans, RP ;

De La Rosette, JJMCH ;

Michel, MC .

BJU INTERNATIONAL, 2005, 95 :19-28

[2] The development of the oral controlled absorption system (OCAS®):: A new improved formulation of tamsulosin [J].

Chapple, CR .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (07) :1-4

[3] Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH):: Efficacy and tolerability in a placebo and active comparator controlled phase 3a study [J].

Chapple, CR ;

Al-Shukri, SH ;

Gattegno, B ;

Holmes, S ;

Martínez-Sagarra, JM ;

Scarpa, RM ;

Trip, OBV ;

Vik, V ;

van der Putten-Slob, I .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :33-44

[4] Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a phase 2b dose-response study [J].

Chapple, CR ;

Lorenz, J ;

Mortensen, R ;

Pauthner, H ;

Reise, MO ;

Schulman, CC ;

van der Putten-Slob, I .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :25-32

[5] Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia:: A retrospective cohort study [J].

Chrischilles, E ;

Rubenstein, L ;

Chao, J ;

Kreder, KJ ;

Gilden, D ;

Shah, H .

CLINICAL THERAPEUTICS, 2001, 23 (05) :727-743

[6]

Coffey DS, 1998, BRIT J UROL, V81, P1

[7] Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: Impact on safety and well-being [J].

de Mey, C .

EUROPEAN UROLOGY, 1998, 34 :18-28

[8] Tamsulosin - An update of its role in the management of lower urinary tract symptoms [J].

Lyseng-Williamson, KA ;

Jarvis, B ;

Wagstaff, AJ .

DRUGS, 2002, 62 (01) :135-167

[9] The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®) [J].

Michel, MC ;

Korstanje, C ;

Krauwinkel, W ;

Kuipers, M .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :15-24

[10] Cardiovascular safety of tamsulosin modified release in the fasted and fed state in elderly healthy subjects [J].

Michel, MC ;

Korstanje, C ;

Krauwinkel, W .

EUROPEAN UROLOGY SUPPLEMENTS, 2005, 4 (02) :9-14

← 1 2 →